In advanced lung cancer, similar to EGFR tyrosine kinase inhibitor (EGFR-TKI) for EGFR-mutated patients, ALK-TKI has a higher objective response rate (ORR) and longer progression-free survival (PFS) for ALK-rearranged patients compared to traditional chemotherapy (6, 7), so neoadjuvant therapy for ALK-positive patients also worth exploring. The gene discussed is ALK; the disease is lung carcinoma.